The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.
Jesus Garcia-Foncillas
No relevant relationships to disclose
Purificación Martinez
No relevant relationships to disclose
Ainhara Lahuerta
No relevant relationships to disclose
Antonio Llombart Cussac
No relevant relationships to disclose
Maria Garcia Gonzalez
No relevant relationships to disclose
Rosa Maria Sanchez Gomez
No relevant relationships to disclose
Isabel Alvarez
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Jose J. Illarramendi
No relevant relationships to disclose
Ana De Juan
No relevant relationships to disclose
Elena Galve Calvo
No relevant relationships to disclose
Arrate Plazaola
No relevant relationships to disclose
Serafin Morales
No relevant relationships to disclose
Blanca Hernando
No relevant relationships to disclose
Juan Lao
No relevant relationships to disclose
Valentina Boni
No relevant relationships to disclose
Teresa Puertolas
No relevant relationships to disclose
Stefan Sherer
No relevant relationships to disclose
Gemma Palacios
No relevant relationships to disclose
Jose Manuel Lopez-Vega
No relevant relationships to disclose